PureTech Health plc (OTCMKTS:PTCHF – Get Rating) was the target of a large decrease in short interest in April. As of April 15th, there was short interest totaling 1,800 shares, a decrease of 33.3% from the March 31st total of 2,700 shares. Based on an average daily volume of 6,000 shares, the days-to-cover ratio is currently 0.3 days.
Shares of PureTech Health stock opened at $2.22 on Friday. The firm’s 50-day simple moving average is $2.67 and its 200-day simple moving average is $3.59. PureTech Health has a 1 year low of $2.13 and a 1 year high of $5.82.
About PureTech Health (Get Rating)
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial aging, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions.
Receive News & Ratings for PureTech Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for PureTech Health and related companies with MarketBeat.com’s FREE daily email newsletter.